Non-clinical safety assessment of gene therapy (pcca, mmab, DOK7 and colq) to support platform gene therapy for congenital myasthenic diseases (DOK7, colq) and acidemia (pcca, mmab)
Active Awarded Last action
- Contract number
- 75N95020F00001
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,298,497
Award facts
- Opportunity
-
- CRO Support for NCATS In Vitro and In Vivo Toxicology Studies Pre-Solicitation · N01TR17200219 · Posted Apr 7, 2020
- Contract value 65% obligated
-
- $5,298,497.16 Current, with exercised options
- $8,098,466.16 Potential, with all options
- Completion date 91% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albuquerque, NM 87108, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $1,282,991 | |
| Exercise an Option | $1,745,514 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Original award | $2,269,992 |
About this award
The National Institute on Drug Abuse issued a delivery order to Lovelace Biomedical Research Institute on September 25, 2020, with a ceiling value of $8,098,466.16 under the CRO Support for NCATS In Vitro and In Vivo Toxicology Studies IDIQ. The order is priced on a cost-plus-fixed-fee basis and covers non-clinical safety assessment of gene therapy platforms (PCCA, MMAB, DOK7, and COLQ) to support treatment of congenital myasthenic diseases and acidemia, with in vitro and in vivo toxicology studies.
Place of performance is Albuquerque, NM. Performance is scheduled through May 31, 2027.
Service Contract Inventory reporting shows minimal labor deployment in the order's active fiscal years. FY2024 invoiced $13,000 across 0.1 FTEs and 150 contractor hours at a derived rate of $87.49 per hour. FY2021 reported 68 contractor hours at $77.42 per hour on $5,000 invoiced. The prime self-performed all reported hours with no subcontractor engagement.
Quick answers
Who was awarded contract 75N95020F00001?
75N95020F00001 was awarded to Lovelace Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on September 25, 2020.
How much is contract 75N95020F00001 worth?
The government has obligated $5,298,497 on 75N95020F00001. Its potential value, with all options, is $8,098,466.
Is contract 75N95020F00001 an order under another contract?
Yes. 75N95020F00001 is a delivery order under HHSN271201700017I, an indefinite delivery contract, on CRO Support for NCATS In Vitro and In Vivo Toxicology Studies.
Was contract 75N95020F00001 competed?
The extent of competition for 75N95020F00001 was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award